Arca Biopharma Up Agreement For Covid: 19 treatment patent rights

Oruka Therapeutics

07/07/2021 13:52

** Drug developer's shares  ABIO.O  rise 2.9% to $3.52
premarket
    ** Co enters into patent assignment agreement with
University Medical Center of Johannes Gutenberg University Mainz
(https://refini.tv/3xjG1Rk)
    ** ABIO receives exclusive world-wide patent rights to use
rNAPc2 as a potential treatment for COVID-19, and other
indications, based on the research at the university's Center
for Thrombosis and Hemostasis 
    ** ABIO is developing rNAPc2 as a potential treatment for
COVID-19 and other viral infection and is currently being tested
in a mid-stage trial in patients hospitalized with COVID-19
    ** ABIO has potential upfront and milestone obligations of
up to 1.6 mln euro and royalty obligations if rNAPc2 receives
regulatory approval and is commercialized
    ** Stock was down about 15% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))